Imaging of programmed cell death ligand 1: Impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma

Journal of Nuclear Medicine

Volumn 58, Issue 10, 2017, Pages 1560-1566

  Nedrow, Jessie R ^a   Josefsson, Anders ^a   Park, Sunju ^a   Ranka, Sagar ^a   Roy, Sanchita ^a   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti PD L1; Immune checkpoint inhibitors; Melanoma; SPECT; Targeted antibodies

Indexed keywords

DIETHYLENETRIAMINEPENTAACETIC ACID INDIUM IN 111 PROGRAMMED CELL DEATH LIGAND 1 ANTIBODY; PENTETATE INDIUM IN 111; PROGRAMMED DEATH 1 LIGAND 1; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; PENTETIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; IMMUNOCOMPETENCE; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; ANIMAL; C57BL MOUSE; CHEMISTRY; DIAGNOSTIC IMAGING; DISEASE MODEL; IMMUNOLOGY; METABOLISM; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD274; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOCOMPETENCE; IMMUNOCONJUGATES; MELANOMA; MICE; MICE, INBRED C57BL; PENTETIC ACID; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 85030833932     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.117.193268     Document Type: Article

References (27)

1. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587-600.
2. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
5. Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4(1) and CD8(1) T cells and is overcome by IL-2. Eur J Immunol. 2002;32: 634-643.
6. Murray JM, Kaufmann GR, Hodgkin PD, et al. Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. Immunol Cell Biol. 2003;81:487-495.
7. Liu Q, Lu JY, Wang XH, Qu BJ, Li SR, Kang JR. Changes in the PD-1 and PDL1 expressions of splenic dendritic cells in multiple-organ dysfunction syndrome mice and their significance. Genet Mol Res. 2014;13:7666-7672.
8. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567.
9. Kim MY, Koh J, Kim S, Go H, Jeon YK, Chung DH. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer. 2015;88:24-33.
10. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.
11. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.
12. Josefsson A, Nedrow JR, Park S, et al. Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Res. 2016;76:472-479.
13. Brechbiel MW. Bifunctional chelates for metal nuclides. Q J Nucl Med Mol Imaging. 2008;52:166-173.
14. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24: 207-212.
15. Beaino W, Nedrow JR, Anderson CJ. Evaluation of 68Ga- and 177Lu-DOTAPEG4-LLP2A for VLA-4-targeted PET imaging and treatment of metastatic melanoma. Mol Pharm. 2015;12:1929-1938.
16. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol. 1979;97:587-600.
17. Adiseshaiah PP, Patel NL, Ileva LV, Kalen JD, Haines DC, McNeil SE. Longitudinal imaging of cancer cell metastases in two preclinical models: a correlation of noninvasive imaging to histopathology. Int J Mol Imaging. 2014: 102702.
18. Branderhorst W, Vastenhouw B, Beekman FJ. Pixel-based subsets for rapid multi-pinhole SPECT reconstruction. Phys Med Biol. 2010;55:2023-2034.
19. Nedrow JR, Latoche JD, Day KE, et al. Targeting PSMA with a Cu-64 labeled phosphoramidate inhibitor for PET/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer. Mol Imaging Biol. 2016;18:402-410.
20. Song H, Shahverdi K, Huso DL, et al. 213Bi (a-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 2008;68:3873-3880.
21. Padda SK, Riess JW, Schwartz EJ, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10:500-508.
22. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibodyassociated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016;46:86-88.
23. Palmer DB. The effect of age on thymic function. Front Immunol. 2013;4:316.
24. Chen K, Kolls JK. T cell-mediated host immune defenses in the lung. Annu Rev Immunol. 2013;31:605-633.
25. Igarashi T, Teramoto K, Ishida M, Hanaoka J, Daigo Y. Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. ESMO Open. 2016;1:e000083.
26. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064-5074.
27. Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G. Highresolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics. 2016;6:1629-1640.